I agree Snapiti - I would have left these announcements until AFTER the sales revenue announcement....perhaps in June after the publication was in the open.
Printable View
And the wheel is ticking?
Could happen but I doubt they would offer enough to reflect the true potential value of the companies products.Medical companies clocks run very slow, think of all the cures for various cancers found in the US over the last few years, how long before any of them get to market? use a 5-10 year timeframe and that would be pretty much on the money.
The market doesn't seem to like good announcements!
Some must be scratching their heads over the SP action on a day with 2 announcements.
I guess that investors want to see numbers rather than words at this stage,but it seems like it would have just stayed around the same rather than the fall......???
Thats true Couts--Lately the whole market has been in a bit of a fowl mood (dont say it Tsuba)
Im starting to get an uneasy feeling --Ive sold all but GNE (waiting for an off market transfer-and one small biotek and I think that may be going--(Its not PEB. for those who think Im down ramping)--
Im thinkin cash ATM (markets dont go up forever)
Come on mate, 120k worth of shares. Expect a little better from a Guru. I'd imagine its worth less than your fishing boat?
We know this company is facing headwinds, it will need too move goalposts, its learning as it goes. its called business. Some investors have the nuggets for it, others sit on the side lines.
Again, the importance of sensitivity, Peb is undoing the bad reputation of current products and yes its pebble by pebble stuff.
I'm thinking total revenue between 2.9-4.
I was a little disappointed I couldn't get any grease from the Cellmid quarterly.
But, the talk will be about Lab output, my gut is telling me divide the trading revenue by $500 and multiply by 3-5 to get total lab output.
Anyway, Tight Lines
“Laboratory throughput continues to track to the company’s expectations following an active direct sales and marketing program to clinicians and healthcare organisations”
It could be misinterpreted as being a little ostentatious when a company is not quite yet in a position to provide numerical guidance.
The reporting period ended five weeks ago though and David Darling will indeed have the sales figures on his desk.
And, the FY15 result will include the first six months of contribution from the sales team of 12 staff hired just last year, perhaps he has good and valid reason for expressing confidence.
Lab throughput is important to the company as it demonstrates to CMS and the private insurers also that Pacific Edge is accumulating adequate case files that demonstrate adoption. Either through user programmes or through studies like the Breen paper announce yesterday.
My view is that early sales are largely irrelevant as a measure of progress, it’s the commercialisation sequence that is important as a gauge in assessing progress toward the $100M revenue goal at FY19.
Having said that it would be satisfying for many shareholders I think to see a peg placed at the bottom of a revenue curve about now, but in recognising sales for molecular diagnostic companies come with coverage, and that will start with CMS soon.
Here’s my estimate based on the recent presentation to Australian investors;
https://www.nzx.com/files/attachments/209911.pdf
http://s300.photobucket.com/user/mcl...tml?sort=3&o=2
Attachment 7334